

Inimex Pharmaceuticals clinic roundup

BioWorld, April 29, 2009 - Inimex Pharmaceuticals Inc., of Vancouver, British Columbia, said it began administering IMX942, an innate defense regulator, in healthy volunteers in a Phase I study. The goal is to demonstrate safety and biological effects in humans, and the firm plans to launch a Phase IIa trial in patients at risk of infection in 2010. IMX942 is designed to bind to an intracellular adaptor protein and modify the signaling network downstream of TLR, TNF and IL-1 receptors. It has no direct antibacterial activity but is aimed at controlling infections in high-risk patients in the hospital setting.